Publications 2020

Byrgazov K, Anderson C, Salzer B, Bozsaky E, Larsson R, Gullbo J, Lehner M, Lehmann F, Slipicevic A, Kager L, Fryknäs M, Taschner-Mandl S (2020)
Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide
Ther Adv Med Oncol, 12, 1758835920937891
DOI 10.1177/1758835920937891, PubMed 32774473

Byrgazov K, Kraus M, Besse A, Slipicevic A, Lehmann F, Driessen C, Besse L (2020)
Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs
Leuk Res, 101, 106499 (in press)
DOI 10.1016/j.leukres.2020.106499, PubMed 33422770

Juraleviciute M, Pozniak J, Nsengimana J, Harland M, Randerson-Moor J, Wernhoff P, Bassarova A, Oy GF, Troen G, Florenes VA, Bishop DT, Herlyn M, Newton-Bishop J, Slipicevic A (2020)
MX 2 is a novel regulator of cell cycle in melanoma cells
Pigment Cell Melanoma Res., 33 (3), 446-457

Schepsky A, Traustadottir GA, Joelsson JP, Ingthorsson S, Kricker J, Bergthorsson JT, Asbjarnarson A, Gudjonsson T, Nupponen N, Slipicevic A, Lehmann F, Gudjonsson T (2020)
Melflufen, a peptide-conjugated alkylator, is an efficient anti-neo-plastic drug in breast cancer cell lines
Cancer Med, 9 (18), 6726-6738
DOI 10.1002/cam4.3300, PubMed 32717133

Publications 2019

Juraleviciute M, Pozniak J, Nsengimana J, Harland M, Randerson-Moor J, Wernhoff P, Bassarova A, Øy GF, Trøen G, Flørenes VA, Bishop DT, Herlyn M, Newton-Bishop J, Slipicevic A (2019)
MX 2 is a novel regulator of cell cycle in melanoma cells
Pigment Cell Melanoma Res, 33 (3), 446-457
DOI 10.1111/pcmr.12837, PubMed 31660681

Publications 2018

Wang Z, Førsund MS, Trope CG, Nesland JM, Holm R, Slipicevic A (2018)
Evaluation of CHK1 activation in vulvar squamous cell carcinoma and its potential as a therapeutic target in vitro
Cancer Med, 7 (8), 3955-3964
DOI 10.1002/cam4.1638, PubMed 29963769

Publications 2017

Li X, Lu J, Kan Q, Li X, Fan Q, Li Y, Huang R, Slipicevic A, Dong HP, Eide L, Wang J, Zhang H, Berge V, Goscinski MA, Kvalheim G, Nesland JM, Suo Z (2017)
Metabolic reprogramming is associated with flavopiridol resistance in prostate cancer DU145 cells
Sci Rep, 7 (1), 5081
DOI 10.1038/s41598-017-05086-6, PubMed 28698547

Publications 2016

Nymoen DA, Slipicevic A, Holth A, Emilsen E, Hetland Falkenthal TE, Tropé CG, Reich R, Flørenes VA, Davidson B (2016)
MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma
Hum Pathol, 54, 74-81
DOI 10.1016/j.humpath.2016.03.010, PubMed 27063471

Publications 2015

Flørenes VA, Emilsen E, Dong HP, Førsund M, Holm R, Slipicevic A (2015)
Cellular localization of CIP2A determines its prognostic impact in superficial spreading and nodular melanoma
Cancer Med, 4 (6), 903-13
DOI 10.1002/cam4.425, PubMed 25663244

Magnussen GI, Emilsen E, Giller Fleten K, Engesæter B, Nähse-Kumpf V, Fjær R, Slipicevic A, Flørenes VA (2015)
Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma
BMC Cancer, 15, 462
DOI 10.1186/s12885-015-1474-8, PubMed 26054341

Slipicevic A, Herlyn M (2015)
KIT in melanoma: many shades of gray
J Invest Dermatol, 135 (2), 337-338
DOI 10.1038/jid.2014.417, PubMed 25573046

Wang Z, Slipicevic A, Førsund M, Trope CG, Nesland JM, Holm R (2015)
Expression of CDK1(Tyr15), pCDK1(Thr161), Cyclin B1 (total) and pCyclin B1(Ser126) in vulvar squamous cell carcinoma and their relations with clinicopatological features and prognosis
PLoS One, 10 (4), e0121398
DOI 10.1371/journal.pone.0121398, PubMed 25849598

Publications 2014

Slipicevic A, Holth A, Hellesylt E, Tropé CG, Davidson B, Flørenes VA (2014)
Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions
Gynecol Oncol, 135 (1), 118-24
DOI 10.1016/j.ygyno.2014.07.102, PubMed 25093290

Slipicevic A, Somasundaram R, Sproesser K, Herlyn M (2014)
Isolation of melanoma cell subpopulations using negative selection
Methods Mol Biol, 1102, 501-12
DOI 10.1007/978-1-62703-727-3_26, PubMed 24258995

Webster MR, Xu M, Kinzler KA, Kaur A, Appleton J, O'Connell MP, Marchbank K, Valiga A, Dang VM, Perego M, Zhang G, Slipicevic A, Keeney F, Lehrmann E, Wood W, Becker KG, Kossenkov AV, Frederick DT, Flaherty KT, Xu X, Herlyn M, Murphy ME, Weeraratna AT (2014)
Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells
Pigment Cell Melanoma Res, 28 (2), 184-95
DOI 10.1111/pcmr.12330, PubMed 25407936

Publications 2012

Magnussen GI, Holm R, Emilsen E, Rosnes AK, Slipicevic A, Flørenes VA (2012)
High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy
PLoS One, 7 (6), e38254
DOI 10.1371/journal.pone.0038254, PubMed 22719872

Slipicevic A, Herlyn M (2012)
Narrowing the knowledge gaps for melanoma
Ups J Med Sci, 117 (2), 237-43
DOI 10.3109/03009734.2012.658977, PubMed 22339359

Slipicevic A, Holm R, Emilsen E, Ree Rosnes AK, Welch DR, Mælandsmo GM, Flørenes VA (2012)
Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival
BMC Cancer, 12, 73
DOI 10.1186/1471-2407-12-73, PubMed 22356677

Slipicevic A, Øy GF, Rosnes AK, Stakkestad Ø, Emilsen E, Engesæter B, Mælandsmo GM, Flørenes VA (2012)
Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis
Cancer Biol Ther, 14 (2), 146-54
DOI 10.4161/cbt.22953, PubMed 23192275

Publications 2010

Oy GF, Slipicevic A, Davidson B, Solberg Faye R, Maelandsmo GM, Flørenes VA (2010)
Biological effects induced by insulin-like growth factor binding protein 3 (IGFBP-3) in malignant melanoma
Int J Cancer, 126 (2), 350-61
DOI 10.1002/ijc.24727, PubMed 19588500

Slipicevic A (2010)
Studies of the PI3K/Akt and MAPK/ERK1/2 signaling pathways: identification of novel downstream targets involved in development and progression of melanoma
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 928, 1 b. (flere pag.)
BIBSYS 101119917, ISBN 978-82-8072-599-8

Publications 2009

Slipicevic A, Øy GF, Askildt IC, Holth A, Hellesylt E, Flørenes VA, Davidson B (2009)
Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions
Hum Pathol, 40 (4), 527-37
DOI 10.1016/j.humpath.2008.10.003, PubMed 19121847

Publications 2008

Slipicevic A, Jørgensen K, Skrede M, Rosnes AK, Trøen G, Davidson B, Flørenes VA (2008)
The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells
BMC Cancer, 8, 276
DOI 10.1186/1471-2407-8-276, PubMed 18826602

Torlakovic EE, Slipicevic A, Flørenes VA, Chibbar R, DeCoteau JF, Bilalovic N (2008)
Fli-1 expression in malignant melanoma
Histol Histopathol, 23 (11), 1309-14
DOI 10.14670/HH-23.1309, PubMed 18785112

Publications 2007

Davidson B, Hadar R, Schlossberg A, Sternlicht T, Slipicevic A, Skrede M, Risberg B, Flørenes VA, Kopolovic J, Reich R (2007)
Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma
Hum Pathol, 39 (1), 87-95
DOI 10.1016/j.humpath.2007.05.014, PubMed 17949781

Publications 2006

Torlakovic E, Slipicevic A, Robinson C, DeCoteau JF, Alfsen GC, Vyberg M, Chibbar R, Flørenes VA (2006)
Pax-5 expression in nonhematopoietic tissues
Am J Clin Pathol, 126 (5), 798-804
DOI 10.1309/XEC7-JMW9-YRM7-4RNO, PubMed 17050077

Publications 2005

Jørgensen K, Skrede M, Cruciani V, Mikalsen SO, Slipicevic A, Flørenes VA (2005)
Phorbol ester phorbol-12-myristate-13-acetate promotes anchorage-independent growth and survival of melanomas through MEK-independent activation of ERK1/2
Biochem Biophys Res Commun, 329 (1), 266-74
DOI 10.1016/j.bbrc.2005.01.143, PubMed 15721302

Slipicevic A (2005)
Signaling mechanisms involved in development and progression of malignant melanoma
A. Slipicevic, Oslo, 1 b. (flere pag.)
BIBSYS 050953427

Slipicevic A, Holm R, Nguyen MT, Bøhler PJ, Davidson B, Flørenes VA (2005)
Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome
Am J Clin Pathol, 124 (4), 528-36
DOI 10.1309/YT58WWMTA6YR1PRV, PubMed 16146807